#USA #Indianapolis #ASP Isotopes #Terbium-161 #Gadolinium-160

Strategic Agreement Between ASP Isotopes and Isotopia

ASP Isotopes Inc. has partnered with Isotopia Molecular Imaging Ltd. in a groundbreaking agreement aimed at securing Gadolinium-160 (Gd-160) supply. This pivotal move is designed to accelerate the production of Terbium-161 (Tb-161), a promising medical isotope that holds great potential for advanced cancer therapies, particularly for prostate cancer and neuroendocrine tumors.

Collaborative Efforts to Overcome Supply Challenges

The historical shortages in the supply of Gd-160 have posed a significant challenge in the production of Tb-161. With their newly forged partnership, ASP Isotopes, leveraging its proprietary Quantum Enrichment technology, will provide Isotopia with enriched Gd-160. This isotope is crucial for the manufacturing process of Tb-161. The collaboration combines ASP's large-scale isotope enrichment expertise—demonstrated in their previous achievements with Ytterbium-176 (Yb-176)—with Isotopia's established capability in producing medical isotopes on a commercial scale. Isotopia has been effectively producing Lutetium-177 (Lu-177) and has maintained a consistent output of Tb-161 for clinical trials over the past two years, marking a significant step in radiotherapeutic advancements.

Paul Mann, CEO of ASP Isotopes, remarked, "By supplying Gd-160, we are eliminating a significant bottleneck in the development of Tb-161 therapies. Our investment in innovative enrichment technology aligns with the rising demand for stable isotopes in the radiopharmaceutical industry. This partnership not only accelerates the path to clinical adoption of Tb-161 but also has the potential to redefine cancer treatment paradigms."

The Therapeutic Promise of Terbium-161

The dual-action mechanism of Tb-161, characterized by its Auger electron emissions, enables targeted destruction of micro-metastases with minimal collateral damage to healthy tissue. Dr. Eli Shalom, CEO of Isotopia, underscored Tb-161’s advantages: "This partnership will ensure a steady Gd-160 supply chain, enabling us to scale production and move toward commercialization of our Tb-161-labeled drug candidates. We operate from our facility in Israel, with production set to commence at our second site in Indianapolis, USA."

With its Auger electrons, Tb-161 can induce double-strand DNA breaks in cancer cells, showcasing potential benefits over traditional therapies such as Lu-177 and alpha-emitting isotopes. The precision targeting aligns perfectly with the oncology field's shift toward radiotherapeutics that enhance treatment efficacy while reducing side effects.

The global interest in radiopharmaceuticals is soaring, largely driven by their ability to provide localized radiation therapy through tumor-seeking molecules. As both companies position themselves at the cutting edge of this technological revolution, they are set to expand treatment options for cancer patients worldwide.

About the Companies

ASP Isotopes Inc.

ASP Isotopes specializes in advanced methods of isotope separation, including its unique Aerodynamic Separation Process and Quantum Enrichment technologies. These innovations allow for the production of stable isotopes without generating radioactive waste. The company's initial efforts are directed toward developing and commercializing highly enriched isotopes for use in healthcare and technology. They operate isotope enrichment facilities in Pretoria, South Africa.

Isotopia Molecular Imaging Ltd.

As a leading entity in medical isotope production, Isotopia boasts facilities across Israel, Europe, and the USA. Its comprehensive platform encompasses cyclotrons, production sites for Lu-177 and Tb-161, alongside sterile manufacturing abilities. The company partners with clinical researchers and healthcare professionals to create novel radiopharmaceuticals tailored for diagnostics and targeted therapies.

In conclusion, this partnership between ASP Isotopes and Isotopia not only tackles existing supply challenges but also heralds a new era of enhanced cancer treatment options, promising brighter prospects for patients in need of innovative therapies.